Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with limb-girdle muscular dystrophy (LGMD) 2I/R9, with no dose-limiting toxicities or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback